Alaunos Therapeutics Inc ((TCRT)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Alaunos Therapeutics Inc. recently updated its clinical study titled ‘A Phase I/II Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects.’ The study aimed to assess the safety and tolerability of Ad-RTS-hIL-12 with veledimex in pediatric patients with brain tumors, including DIPG, to enhance the immune system’s ability to target tumor cells.
The intervention tested includes Ad-RTS-hIL-12, a biological agent, and oral veledimex, a drug. This combination is designed to stimulate the production of IL-12, a protein that can boost the immune response against tumors.
The study was interventional, non-randomized, and followed a single-group model with no masking. Its primary purpose was treatment-focused, aiming to evaluate the safety and tolerability of the intervention.
The study began on September 26, 2017, and was terminated before completion. The primary completion date was set for February 28, 2025, with the last update on August 10, 2025. These dates highlight the study’s timeline and its early termination.
The termination of this study could impact Alaunos Therapeutics’ stock performance and investor sentiment, as it may raise concerns about the viability of the treatment. This development could also affect the competitive landscape in the pediatric brain tumor treatment market.
The study has been terminated, and further details are available on the ClinicalTrials portal.